Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > IR responce

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on Feb 11, 2021 1:24pm

105 Views

Post# 32542207

RE:RE:RE:IR responce

i think, first they paid 100m to obtain the license in china. the double digit royalties from revenues will benefit antibe later on. This will give you an idea on how strong is the proof of concept. i think nuance will wait for phase 3 results in us. it will file it in china after, this way it will reduce the costs of clinical trials. nuance will be responsible for manifacturing and marketing our drug in china , in return we will get royalties.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec